

COMPUGEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except for share and per-share amounts)

	Three Months Ended	
	<u>March 31</u>	
	<u>2011</u>	<u>2010</u>
	<u>Unaudited</u>	<u>Unaudited</u>
Revenues	-	125
Research and development expenses	1,691	1,635
Less: governmental and other grants	(48)	-
Research and development expenses, net	1,643	1,635
Marketing and business development expenses	148	188
General and administrative expenses	643	1,020
Total operating expenses *	2,434	2,843
Operating loss	(2,434)	(2,718)
Financial income (expenses), net	294	(1)
Other income	240	-
Net loss	(1,900)	(2,719)
Basic and diluted net loss per ordinary share	(0.06)	(0.08)
Weighted average number of ordinary shares outstanding	34,091,738	33,010,196

* Includes stock based compensation

COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars, in thousands)

	March 31, <u>2011</u> <u>Unaudited</u>	December 31, <u>2010</u> <u>Audited</u>
ASSETS		
Current assets		
Cash, cash equivalents and short-term bank deposits	25,532	21,824
Restricted cash	99	684
Trade receivables	-	21
Accounts receivable and prepaid expenses	840	548
Receivables from funding arrangement	-	5,000
Total current assets	26,471	28,077
Long-term investments		
Investment in Evogene	5,794	6,227
Long-term prepaid expenses	70	64
Severance pay fund	1,535	1,510
Total long-term investments	7,399	7,801
Property and equipment, net	557	580
Total assets	34,427	36,458
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued expenses	1,596	2,441
Total current liabilities	1,596	2,441
Long-term liabilities		
Research and development funding arrangement	4,213	4,037
Accrued severance pay	1,699	1,695
Total long-term liabilities	5,912	5,732
Total shareholders' equity	26,919	28,285
Total liabilities and shareholders' equity	34,427	36,458